Similarly, no significant differences in TIM-3+ frequencies showed in CD34+CD38− and CD34+CD38+ cells between t(8;21) and inv(16) subtypes (p = 0.47 and 0.85), but both showed significantly higher TIM-3+ frequencies in CD34+CD38− cells (13.1% (0.24–34.9%) vs. 4.2% (0.21–53.2%), p = 0.004; 13.2% (5.1–35.4%) vs. 4.2% (0.21–53.2%), p = 0.012) and CD34+CD38+ cells (19.9% (2.7–66.6%) vs. 4.5% (0.10–75.4%), p < 0.001; 22.4% (8.5–34.1%) vs. 4.5% (0.10–75.4%), p = 0.005) compared to non-CBF-AML. This evidence concerns the gene CD34 and acute myeloid leukemia.